top of page
News, Events and Updates
Search
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Apr 11, 2024
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Mar 18, 2024
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Feb 26, 2024
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Feb 1, 2024
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Jan 24, 2024
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 16, 2024
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Nov 27, 2023
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Nov 24, 2023
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
Aug 8, 2023
Anavex Life Sciences Reports Publication of ANAVEX®3-71
Aug 7, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 20, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
May 2, 2023
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Feb 7, 2023
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 21, 2022
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Jan 10, 2022
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
Jul 6, 2020
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)
May 21, 2020
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
